PaxMedica Enters Research Collaboration Agreement With PoloMar Health for Phase II Study in Autism Spectrum Disorder
08 juin 2023 08h00 HE
|
PaxMedica, Inc.
Collaboration Will Investigate a Next Generation Orally Delivered Anti-Purinergic Compound Proof-of-Concept Study Based on one of PaxMedica’s Proprietary Pipeline Candidates TARRYTOWN, NY, June ...
Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering
26 mai 2023 16h05 HE
|
Biodexa Pharmaceuticals PLC
26 May 2023 Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a...
Biodexa Pharmaceuticals PLC Announces US$3.32 Million Registered Direct Offering
24 mai 2023 08h40 HE
|
Biodexa Pharmaceuticals PLC
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH...
Posting of Annual Report & Notice of AGM
22 mai 2023 16h15 HE
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Posting of Annual Report & Notice of AGM Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company...
Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals
18 mai 2023 08h30 HE
|
Biodexa Pharmaceuticals PLC
18 May 2023 Biodexa Pharmaceuticals Enters into Non-binding Letter of Intent for Proposed Acquisition of Varian Biopharmaceuticals Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) (“Biodexa” or the...
Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023
11 mai 2023 10h20 HE
|
Cellectis Inc.
NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Monthly information on share capital and company voting rights
10 mai 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, May 10, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting...
The Acquired Aplastic Anemia Market is Projected To Reach USD 10.25 billion By 2030, From USD 7.27 billion in 2022,Registering a CAGR Of 4.20% During The Forecast Period 2023-2030| Data By Contrive Datum Insights Pvt Ltd.
08 mai 2023 13h20 HE
|
Contrive Datum Insights Pvt Ltd
Farmington, May 08, 2023 (GLOBE NEWSWIRE) -- The Global Acquired Aplastic Anemia Market size was valued at USD 7.27 billion in 2022 and is projected to reach USD 10.25 billion by 2030, growing at a...
Biopharmaceutical Excipient Manufacturing Market Grow at a CAGR of 9.7% from 2023 to 2031 | Latest InsightAce Report
05 mai 2023 07h07 HE
|
InsightAce Analytic Pvt. LTd.
Jersey City, NJ, May 05, 2023 (GLOBE NEWSWIRE) -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the Global Biopharmaceutical Excipient Manufacturing Market- by...
Preliminary Results for the Year Ended 31 December 2022
28 avr. 2023 16h30 HE
|
Biodexa Pharmaceuticals PLC
28 April 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2022 Biodexa Pharmaceuticals...